{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T08:42:09.171509+00:00","company":{"ticker":"RGNX","cik":1590877,"company_name":"REGENXBIO Inc."},"pagination":{"limit":100,"returned":14,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"shareholder_vote","fact_key":"d4ec1a0d3d9225735a3fd8416ab1c2d33a39acd4","cik":1590877,"ticker":"RGNX","company_name":"REGENXBIO Inc.","filed_at":"2026-06-03T11:30:16+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-29","outcome":"failed","proposal_text":"Stock Option Exchange Program for executive employees","proposal_type":"other","results":[{"broker_non_votes":"7,554,121","subject":null,"votes_abstain":"145,416","votes_against":"21,021,531","votes_for":"14,097,815","votes_withheld":null}]},"claim":"REGENXBIO Inc. shareholders rejected Stock Option Exchange Program for executive employees at the 2026-05-29 meeting.","evidence_excerpt":"Proposal 5 : By the following vote, the stockholders did not approve, a Stock Option Exchange Program for the Company’s executive employees: Votes For Votes Against Votes Abstaining Broker Non-Votes 14,097,815 21,021,531 145,416 7,554,121","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-254590","anchor_url":"https://secwatch.observer/filing/0001193125-26-254590#claim-d4ec1a0d3d9225735a3fd8416ab1c2d33a39acd4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526254590/0001193125-26-254590-index.htm"},{"fact_type":"shareholder_vote","fact_key":"be6dd6ece7801cb88fa6c7c74ba1917d88bd8c32","cik":1590877,"ticker":"RGNX","company_name":"REGENXBIO Inc.","filed_at":"2026-06-03T11:30:16+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-29","outcome":"passed","proposal_text":"Approval of Stock Option Exchange Program for non-executive employees","proposal_type":"equity_plan","results":[{"broker_non_votes":"7,554,121","subject":null,"votes_abstain":"59,076","votes_against":"8,853,230","votes_for":"26,352,456","votes_withheld":null}]},"claim":"REGENXBIO Inc. shareholders approved Approval of Stock Option Exchange Program for non-executive employees at the 2026-05-29 meeting.","evidence_excerpt":"Proposal 4 : By the following vote, the stockholders approved, the Stock Option Exchange Program for the Company’s non-executive employees: Votes For Votes Against Votes Abstaining Broker Non-Votes 26,352,456 8,853,230 59,076 7,554,121","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-254590","anchor_url":"https://secwatch.observer/filing/0001193125-26-254590#claim-be6dd6ece7801cb88fa6c7c74ba1917d88bd8c32","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526254590/0001193125-26-254590-index.htm"},{"fact_type":"shareholder_vote","fact_key":"72064c30e88b973e1723a310d8c34693ae374d1a","cik":1590877,"ticker":"RGNX","company_name":"REGENXBIO Inc.","filed_at":"2026-06-03T11:30:16+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-29","outcome":"passed","proposal_text":"Advisory vote to approve compensation of named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"7,554,121","subject":null,"votes_abstain":"149,635","votes_against":"2,722,825","votes_for":"32,392,302","votes_withheld":null}]},"claim":"REGENXBIO Inc. shareholders approved Advisory vote to approve compensation of named executive officers at the 2026-05-29 meeting.","evidence_excerpt":"Proposal 3 : By the following vote, the stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement: Votes For Votes Against Votes Abstaining Broker Non-Votes 32,392,302 2,722,825 149,635 7,554,121","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-254590","anchor_url":"https://secwatch.observer/filing/0001193125-26-254590#claim-72064c30e88b973e1723a310d8c34693ae374d1a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526254590/0001193125-26-254590-index.htm"},{"fact_type":"shareholder_vote","fact_key":"40f98da7f1142e24fc41779345cefe2371bcd554","cik":1590877,"ticker":"RGNX","company_name":"REGENXBIO Inc.","filed_at":"2026-06-03T11:30:16+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-29","outcome":"passed","proposal_text":"Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"47,545","votes_against":"244,785","votes_for":"42,526,553","votes_withheld":null}]},"claim":"REGENXBIO Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for year ending December 31, 2026 at the 2026-05-29 meeting.","evidence_excerpt":"Proposal 2 : By the following vote, the stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026: Votes For Votes Against Votes Abstaining Broker Non-Votes 42,526,553 244,785 47,545 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-254590","anchor_url":"https://secwatch.observer/filing/0001193125-26-254590#claim-40f98da7f1142e24fc41779345cefe2371bcd554","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526254590/0001193125-26-254590-index.htm"},{"fact_type":"shareholder_vote","fact_key":"81a9944e02c4d970ebb721f5e17475b6cdcdabdc","cik":1590877,"ticker":"RGNX","company_name":"REGENXBIO Inc.","filed_at":"2026-06-03T11:30:16+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-29","outcome":"passed","proposal_text":"Election of three Class II directors","proposal_type":"director_election","results":[{"broker_non_votes":"7,554,121","subject":"Jean Bennett, M.D., Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"24,025,836","votes_withheld":"11,238,926"},{"broker_non_votes":"7,554,121","subject":"A.N. \"Jerry\" Karabelas, Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"27,124,923","votes_withheld":"8,139,839"},{"broker_non_votes":"7,554,121","subject":"Daniel Tassé","votes_abstain":null,"votes_against":null,"votes_for":"32,039,753","votes_withheld":"3,225,009"}]},"claim":"REGENXBIO Inc. shareholders approved Election of three Class II directors at the 2026-05-29 meeting.","evidence_excerpt":"Proposal 1 : By the following vote, the following three persons were elected to serve as Class II directors until the Company’s 2029 annual meeting of stockholders: Nominee Votes For Votes Withheld Broker Non-Votes Jean Bennett, M.D., Ph.D. 24,025,836 11,238,926 7,554,121 A.N. “Jerry” Karabelas, Ph.D. 27,124,923 8,139,839 7,554,121 Daniel Tassé 32,039,753 3,225,009 7,554,121","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-254590","anchor_url":"https://secwatch.observer/filing/0001193125-26-254590#claim-81a9944e02c4d970ebb721f5e17475b6cdcdabdc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526254590/0001193125-26-254590-index.htm"},{"fact_type":"material_agreement","fact_key":"c12e231e4a45f79d0d62d320d32a74dcb40a4903","cik":1590877,"ticker":"RGNX","company_name":"REGENXBIO Inc.","filed_at":"2026-03-20T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Settlement and Release Agreement","agreement_type":"settlement","counterparty":"GlaxoSmithKline LLC","effective_date":"2026-03-18","item_codes_triggered":["1.01"],"value_text":"$10.0 million"},"claim":"REGENXBIO Inc. entered into Settlement and Release Agreement with GlaxoSmithKline LLC valued at $10.0 million (effective 2026-03-18).","evidence_excerpt":"On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-117913","anchor_url":"https://secwatch.observer/filing/0001193125-26-117913#claim-c12e231e4a45f79d0d62d320d32a74dcb40a4903","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/0001193125-26-117913-index.htm"},{"fact_type":"executive_change","fact_key":"ba4fcd8660","cik":1590877,"ticker":"RGNX","company_name":"REGENXBIO Inc.","filed_at":"2024-09-17T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-09-16","interim":false,"role":"Executive Vice President, Chief Financial Officer and Principal Accounting Officer","role_category":"cfo","successor_name":"Mitchell Chan","successor_named":true},"claim":"Vittal Vasista resigned as Executive Vice President, Chief Financial Officer and Principal Accounting Officer at REGENXBIO Inc..","evidence_excerpt":"the Board accepted the resignation of Vittal Vasista from his position as Executive Vice President, Chief Financial Officer and Principal Accounting Officer, effective as of September 16, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-107367","anchor_url":"https://secwatch.observer/filing/0000950170-24-107367#claim-ba4fcd8660","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590877/000095017024107367/0000950170-24-107367-index.htm"},{"fact_type":"executive_change","fact_key":"97469485d9","cik":1590877,"ticker":"RGNX","company_name":"REGENXBIO Inc.","filed_at":"2024-09-17T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-09-16","interim":false,"role":"Executive Vice President, Chief Financial Officer and Principal Accounting Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Mitchell Chan was appointed as Executive Vice President, Chief Financial Officer and Principal Accounting Officer at REGENXBIO Inc..","evidence_excerpt":"On September 16, 2024, the board of directors (the “Board” of REGENXBIO Inc. (the “Company”) appointed Mitchell Chan as Executive Vice President, Chief Financial Officer and Principal Accounting Officer, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-107367","anchor_url":"https://secwatch.observer/filing/0000950170-24-107367#claim-97469485d9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590877/000095017024107367/0000950170-24-107367-index.htm"},{"fact_type":"executive_change","fact_key":"984e5d6f25","cik":1590877,"ticker":"RGNX","company_name":"REGENXBIO Inc.","filed_at":"2024-06-13T23:59:59+00:00","payload":{"action":"succeeded","action_category":"departure","departure_tone":"not_disclosed","effective_date":null,"interim":false,"role":"Lead Independent Director","role_category":"other","successor_name":"Daniel Tassé","successor_named":true},"claim":"Jerry Karabelas departed as Lead Independent Director at REGENXBIO Inc..","evidence_excerpt":"Daniel Tassé was appointed as the Company's Lead Independent Director, succeeding Jerry Karabelas.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-160146","anchor_url":"https://secwatch.observer/filing/0001193125-24-160146#claim-984e5d6f25","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/0001193125-24-160146-index.htm"},{"fact_type":"executive_change","fact_key":"03de9b4477","cik":1590877,"ticker":"RGNX","company_name":"REGENXBIO Inc.","filed_at":"2024-06-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Lead Independent Director","role_category":"other","successor_name":null,"successor_named":false},"claim":"Daniel Tassé was appointed as Lead Independent Director at REGENXBIO Inc..","evidence_excerpt":"Daniel Tassé was appointed as the Company's Lead Independent Director, succeeding Jerry Karabelas.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-160146","anchor_url":"https://secwatch.observer/filing/0001193125-24-160146#claim-03de9b4477","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/0001193125-24-160146-index.htm"},{"fact_type":"executive_change","fact_key":"87d7bec8bd","cik":1590877,"ticker":"RGNX","company_name":"REGENXBIO Inc.","filed_at":"2024-06-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-07-01","interim":false,"role":"Class I director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Curran M. Simpson was appointed as Class I director at REGENXBIO Inc..","evidence_excerpt":"In connection with his appointment, the Board appointed Mr. Simpson as a Class I director, effective July 1, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-160146","anchor_url":"https://secwatch.observer/filing/0001193125-24-160146#claim-87d7bec8bd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/0001193125-24-160146-index.htm"},{"fact_type":"executive_change","fact_key":"445c195975","cik":1590877,"ticker":"RGNX","company_name":"REGENXBIO Inc.","filed_at":"2024-06-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-07-01","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Curran M. Simpson was appointed as President and Chief Executive Officer at REGENXBIO Inc..","evidence_excerpt":"the Company also announced that the Board appointed Curran M. Simpson as President and Chief Executive Officer, effective as of July 1, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-160146","anchor_url":"https://secwatch.observer/filing/0001193125-24-160146#claim-445c195975","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/0001193125-24-160146-index.htm"},{"fact_type":"executive_change","fact_key":"c891955d7e","cik":1590877,"ticker":"RGNX","company_name":"REGENXBIO Inc.","filed_at":"2024-06-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"routine","effective_date":"2024-07-01","interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":"Curran M. Simpson","successor_named":true},"claim":"Kenneth T. Mills was appointed as Chairman of the Board at REGENXBIO Inc..","evidence_excerpt":"accepted the resignation of Kenneth T. Mills from his position as President and Chief Executive Officer of the Company, effective July 1, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-160146","anchor_url":"https://secwatch.observer/filing/0001193125-24-160146#claim-c891955d7e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/0001193125-24-160146-index.htm"},{"fact_type":"earnings_release","fact_key":"473bb221b0fc7009ef36077f0174115b5151b51b","cik":1590877,"ticker":"RGNX","company_name":"REGENXBIO Inc.","filed_at":"2024-05-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ending March 31, 2024","report_date":"2024-05-08","result_type":"reported_results","revenue_text":"$15.6 million"},"claim":"REGENXBIO Inc. reported the first quarter ending March 31, 2024 results: revenue $15.6 million.","evidence_excerpt":"and pre-funded warrants completed in March 2024, and was partially offset by cash used to fund operating activities during the first quarter of 2024. Revenues: Revenues were $15.6 million for the three months ended March 31, 2024, compared to $19.1 million for the three months ended March 31, 2023. The decrease was primarily attributable to non-recurring","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-055656","anchor_url":"https://secwatch.observer/filing/0000950170-24-055656#claim-473bb221b0fc7009ef36077f0174115b5151b51b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590877/000095017024055656/0000950170-24-055656-index.htm"}]}